Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Chronic Heart Failure With Reduced Ejection Fraction
  • Heart Failure

NCT number NCT05093933
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Active, not recruiting
Phase Phase 3
Start date November 2, 2021
Completion date June 15, 2025

See also
  Status Clinical Trial Phase
Completed NCT02861534 - A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) Phase 3
Completed NCT02226120 - Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction Phase 3
Recruiting NCT06148935 - An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
Not yet recruiting NCT06195930 - A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 2
Completed NCT04836182 - A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 2
Recruiting NCT04983043 - Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure Phase 2
Recruiting NCT04840914 - A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction Phase 1
Completed NCT02768298 - Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Phase 4
Active, not recruiting NCT05974189 - The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
Recruiting NCT05553886 - S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction Phase 3
Completed NCT02900378 - randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure Phase 3
Withdrawn NCT04464525 - Omecamtiv Mecarbil Post-trial Access Study Phase 3
Recruiting NCT05658458 - A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction) Phase 4
Recruiting NCT05728502 - An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China